Xu, J., Zhang, X., Yang, H., Ding, G., Jin, B., Lou, Y., . . . Han, B. (2016). Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations. Oncotarget.

Xu, Jianlin, Xueyan Zhang, Haitang Yang, Guozheng Ding, Bo Jin, Yuqing Lou, Yanwei Zhang, Huimin Wang, et Baohui Han. "Comparison of Outcomes of Tyrosine Kinase Inhibitor in First- or Second-line Therapy for Advanced Non-small-cell Lung Cancer Patients With Sensitive EGFR Mutations." Oncotarget 2016.

Xu, Jianlin, et al. "Comparison of Outcomes of Tyrosine Kinase Inhibitor in First- or Second-line Therapy for Advanced Non-small-cell Lung Cancer Patients With Sensitive EGFR Mutations." Oncotarget 2016.